Merck (MRK) Operating Margin (2009 - 2026)
Merck (MRK) reported Operating Margin of 47.46% for Q1 2026, down 6345.0% year-over-year from 0.76% in Q1 2025, and down 265.23% quarter-over-quarter from 12.99% in Q4 2025.
Merck (MRK) Operating Margin (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Operating Margin data on file, last reported at 47.46% in Q1 2026.
- Operating Margin for Q1 2026 came in at 47.46%, down 6345.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 8.41% (down 1638.0% YoY), and the FY2025 annual result was 7.21%, down 19.0% from the prior year.
- Operating Margin fell to 47.46% in Q1 2026 per MRK's latest filing, from 12.99% in the prior quarter.
- Over five years, Operating Margin peaked at 16.73% in Q3 2025 and troughed at 62.25% in Q2 2023.
- A 5-year average of 5.39% and a median of 0.06% in 2024 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2023 and 2024: Operating Margin plunged 6411 bps in 2023, then surged 7628 bps in 2024.
- A 5-year view of Operating Margin shows it stood at 2.66% in 2022, then plunged by 1430 bps to 40.72% in 2023, then soared by 105 bps to 2.19% in 2024, then plunged by 694 bps to 12.99% in 2025, then sank by 265 bps to 47.46% in 2026.
- Business Quant data shows MRK's Operating Margin at 47.46% in Q1 2026, 12.99% in Q4 2025, and 16.73% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 30.06% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 47.98% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 26.44% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 26.60% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -286.83% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -1.58% |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.46% |
| Dec 31, 2025 | -12.99% |
| Sep 30, 2025 | 16.73% |
| Jun 30, 2025 | 9.12% |
| Mar 31, 2025 | 16.00% |
| Dec 31, 2024 | 2.19% |
| Sep 30, 2024 | 0.06% |
| Jun 30, 2024 | 14.03% |
| Mar 31, 2024 | 13.50% |
| Dec 31, 2023 | -40.72% |
| Sep 30, 2023 | 8.50% |
| Jun 30, 2023 | -62.25% |
| Mar 31, 2023 | -1.91% |
| Dec 31, 2022 | -2.66% |
| Sep 30, 2022 | -2.35% |
| Jun 30, 2022 | 1.86% |
| Mar 31, 2022 | -3.26% |
| Dec 31, 2021 | 0.26% |
| Sep 30, 2021 | 13.81% |
| Jun 30, 2021 | -12.16% |